Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald H Sokol

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Pharmacotherapy|March 28, 2008
Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch databaseJames F Knudsen, Gerald H Sokol
The American Journal of Medicine|January 25, 2006
Reply to the Vioxx debacleJames F Knudsen, Gerald H Sokol
Southern Medical Journal|October 4, 2017
Breast Cancer Survivorship: Patient Characteristics and Plans for High-Quality CareLoretta S Loftus, Gerald H Sokol, Christine Laronga
Inflammation|September 1, 2005
The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase IIJames F Knudsen, Uno Carlsson, Per Hammarström, et al.
Investigational New Drugs|September 14, 2020
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancerBenjamin A Gartrell, Mack Roach, Avi Retter, et al.
International Journal of Radiation Oncology, Biology, Physics|June 27, 2006
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus ConferenceMack Roach, Gerald Hanks, Howard Thames, et al.
American Journal of Surgery|August 5, 2015
Intraoperative radiotherapy for early breast cancer and age: clinical characteristics and outcomesAndrea M Abbott, Lesly A Dossett, Loretta Loftus, et al.
The Oncologist|October 29, 2002
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acidMartin H Cohen, Ramzi Dagher, Donna J Griebel, et al.
Journal of the American Medical Directors Association|June 7, 2011
Sarcopenia with limited mobility: an international consensusJohn E Morley, Angela Marie Abbatecola, Josep M Argiles, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Pharmacotherapy|March 28, 2008
Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch databaseJames F Knudsen, Gerald H Sokol
The American Journal of Medicine|January 25, 2006
Reply to the Vioxx debacleJames F Knudsen, Gerald H Sokol
Southern Medical Journal|October 4, 2017
Breast Cancer Survivorship: Patient Characteristics and Plans for High-Quality CareLoretta S Loftus, Gerald H Sokol, Christine Laronga
Inflammation|September 1, 2005
The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase IIJames F Knudsen, Uno Carlsson, Per Hammarström, et al.
Investigational New Drugs|September 14, 2020
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancerBenjamin A Gartrell, Mack Roach, Avi Retter, et al.
International Journal of Radiation Oncology, Biology, Physics|June 27, 2006
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus ConferenceMack Roach, Gerald Hanks, Howard Thames, et al.
American Journal of Surgery|August 5, 2015
Intraoperative radiotherapy for early breast cancer and age: clinical characteristics and outcomesAndrea M Abbott, Lesly A Dossett, Loretta Loftus, et al.
The Oncologist|October 29, 2002
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acidMartin H Cohen, Ramzi Dagher, Donna J Griebel, et al.
Journal of the American Medical Directors Association|June 7, 2011
Sarcopenia with limited mobility: an international consensusJohn E Morley, Angela Marie Abbatecola, Josep M Argiles, et al.
Pageof 1